Projects

This project aims to roll out clinical AMR surveillance as part of routine care in a network of hospitals across Asia and Africa and to collect microbiology and clinical data from 2,500 patients per site, which will expand on the sample-based approach of WHO GLASS and enable classification of infection syndromes, the origin of infection and outcome.

The project aims to develop and validate a novel framework for future surveillance, benchmarking and population-based interventional trials of optimal antibiotic use in low- and middle-income primary care settings.

The project created opportunities for children and teenagers to access books and media to improve their basic knowledge on malaria and chances to discuss about the research.

This project aims to conduct a nationwide assessment of the current state of implementation of hospital ASPs across all 37 provinces to inform stakeholders on the current stage of AMS implementation, their barriers and enablers, and to estimate the impact of COVID-19 at a local level.

This study developed a mathematical model to understand how human movement in Greater Jakarta influenced the spread of COVID-19.

This study helps identify factors associated with multidrug-resistant tuberculosis (MDR-TB) treatment success and will significantly contribute to the evidence base for the development of MDR-TB treatment regimens in the MDR-TB management programme in Vietnam.

This study aims to investigate the causes of the substantial heterogeneity in treatment responses and outcomes from drug-susceptible pulmonary tuberculosis.

The PediPOT study aims to understand and improve outcomes for children with tuberculous meningitis in Vietnam and Indonesia by examining its effects on both mortality and neurodevelopment, assessing various clinical, laboratory, and imaging features, as well as exploring genetic and metabolic factors influencing disease severity and prognosis.

ABACUS phase I (2016-2019) explored antibiotic use and access practices in 6 LMICs and revealed the importance of a context and cultural tailored approach to address responsible antibiotic use in each country. ABACUS phase II (2020-) builds on findings from phase I and aims to investigate the idea of an harmonised physical appearance of antibiotics to facilitate identification from patients and health care professionals.

ACT HIV is a parallel-group, randomised (1:1), double-blind, placebo-controlled multi-centre Phase III trial comparing dexamethasone versus placebo for 6–8 weeks in addition to standard anti-tuberculosis and antiretroviral treatment.

Analyses of correlates of SARS-CoV-2 infection or mortality have usually assessed individual predictors. This study aimed to determine if patterns of combined predictors may better identify risk of infection and mortality.